{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T01:28:52Z","timestamp":1768267732399,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.schres.2021.02.016","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T22:59:24Z","timestamp":1616194764000},"page":"42-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Neuroleptic malignant syndrome associated with long-acting injectable versus oral second-generation antipsychotics: Analyses based on a spontaneous reporting system database in Japan"],"prefix":"10.1016","volume":"231","author":[{"given":"Fuminari","family":"Misawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2021.02.016_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/0006-3223(87)90010-2","article-title":"Neuroleptic malignant syndrome: review and analysis of 115 cases","author":"Addonizio","year":"1987","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2021.02.016_bb0010","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4088\/JCP.v65n0403","article-title":"Neuroleptic malignant syndrome and atypical antipsychotic drugs","volume":"65","author":"Ananth","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2021.02.016_bb0015","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1176\/ajp.147.9.1149","article-title":"Neuroleptic malignant syndrome in 12 of 9,792 Chinese inpatients exposed to neuroleptics: a prospective study","volume":"147","author":"Deng","year":"1990","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2021.02.016_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154425","article-title":"A pharmacovigilance approach for post-marketing in Japan using the Japanese Adverse Drug Event Report (JADER) database and association analysis","volume":"11","author":"Fujiwara","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.schres.2021.02.016_bb0025","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/JCP.0b013e318166c4d5","article-title":"Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review","volume":"28","author":"Gao","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2021.02.016_bb0030","first-page":"426","article-title":"Depot neuroleptic therapy: an underutilized treatment option","volume":"53","author":"Glazer","year":"1992","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2021.02.016_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.113249","article-title":"Trend survey on adverse event profiles of antipsychotic long-acting injections and oral agents using the Japanese adverse drug event report database","volume":"291","author":"Hatano","year":"2020","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2021.02.016_bb0040","doi-asserted-by":"crossref","DOI":"10.1192\/bjp.195.52.s63","article-title":"Clinical guideline recommendations for antipsychotic long-acting injections","author":"Kane","year":"2009","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2021.02.016_bb0045","series-title":"Low incidence of neuroleptic malignant syndrome associated with paliperidone palmitate long-acting","author":"Kane","year":"2019"},{"key":"10.1016\/j.schres.2021.02.016_bb0050","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/archpsyc.1989.01810100056011","article-title":"Risk factors for neuroleptic malignant syndrome: a case-control study","volume":"46","author":"Keck","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2021.02.016_bb0055","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.13r08440","article-title":"Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies","author":"Kishimoto","year":"2013","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.schres.2021.02.016_bb0060","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/schbul\/sbx090","article-title":"Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies","volume":"44","author":"Kishimoto","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2021.02.016_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2016.07.018","article-title":"Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics","volume":"176","author":"Misawa","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2021.02.016_bb0070","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2021.02.016_bb0075","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-0447.2006.00982.x","article-title":"The case for long-acting antipsychotic agents in the post-CATIE era","author":"Nasrallah","year":"2007","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2021.02.016_bb0080","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1177\/070674371205700810","article-title":"Neuroleptic malignant syndrome-an 11-year longitudinal case-control study","volume":"57","author":"Nielsen","year":"2012","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.schres.2021.02.016_bb0085","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/1091581819870717","article-title":"Pharmacovigilance assessment of drug-induced acute pancreatitis using a spontaneous reporting database","volume":"38","author":"Niinomi","year":"2019","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.schres.2021.02.016_bb0090","author":"Pharmaceutical and Medical Device Regulatory Science Society of Japan"},{"key":"10.1016\/j.schres.2021.02.016_bb0095","author":"Pharmaceuticals and Medical Devices Agency"},{"key":"10.1016\/j.schres.2021.02.016_bb0100","doi-asserted-by":"crossref","DOI":"10.1007\/s40263-013-0083-9","article-title":"Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective","author":"Rauch","year":"2013","journal-title":"CNS Drugs."},{"key":"10.1016\/j.schres.2021.02.016_bb0105","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.schres.2021.02.016_bb0110","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/acps.12222","article-title":"Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome","volume":"130","author":"Su","year":"2014","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2021.02.016_bb0115","doi-asserted-by":"crossref","DOI":"10.1111\/appy.12393","article-title":"Patterns of long acting injectable antipsychotic use and associated clinical factors in schizophrenia among 15 Asian countries and region","author":"Tang","year":"2020","journal-title":"Asia Pac. Psychiatry"},{"key":"10.1016\/j.schres.2021.02.016_bb0120","doi-asserted-by":"crossref","DOI":"10.1097\/01.jcp.0000426180.89572.51","article-title":"Neuroleptic malignant syndrome associated with risperidone long-acting injection: a case report","volume":"33","author":"Yamashita","year":"2013","journal-title":"J. Clin. Psychopharmacol."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996421001006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996421001006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:40:29Z","timestamp":1760298029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996421001006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":24,"alternative-id":["S0920996421001006"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2021.02.016","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroleptic malignant syndrome associated with long-acting injectable versus oral second-generation antipsychotics: Analyses based on a spontaneous reporting system database in Japan","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2021.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}